Skip to content

Outcomes Measures in Intellectual Disability

Development and Validation of Quantitative Attention Evaluation Criteria in Patients With Intellectual Disability

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03878251
Acronym
EVALDI
Enrollment
40
Registered
2019-03-18
Start date
2021-07-07
Completion date
2022-06-07
Last updated
2022-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit in Intellectual Disability

Keywords

Intellectual disability, Attention evaluation criteria, Games on touchscreen, Eye tracking

Brief summary

Objective quantitative primary endpoints are lacking in Clinical trials in intellectual disability. We propose to develop quantitative interactive attention evaluation criteria in patients with intellectual disability by using games on touchscreen and or eye tracking.

Detailed description

The aim of the study is to develop and validate quantitative interactive attention evaluation criteria by using games on touchscreen and or eye tracking in patients with intellectual disability. Tests will have to be suitable whatever severity and etiology of intellectual disability. Tests have to evaluate attention and concentration troubles in intellectual disability.Once validated, tests could be used as outcome measures in clinical trials and as cognitive reeducation tools in intellectual disability.

Interventions

DEVICEQuantitative attention evaluation criteria in intellectual disability

Quantitative interactive attention evaluation tests by using games on touchscreen and or eye tracking (oculometer)

Sponsors

Plateforme PRISME
CollaboratorUNKNOWN
Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients of both sex, with intellectual disability 2. Minor patients 6 years old or more (age corresponding to the end of regression period observed in Rett patients) or major protected patients 3. Patients with more or less severe intellectual disability from various causes including Fragile X syndrome, Rett syndrome, Angelman syndrome and other etiologies of intellectual disabilities and intellectual disabilities without identified etiology 4. Affiliation to a social security system own or affiliated (excluding AME) 5. Presence of parents or legal representative 6. Informed consent signed by parents or legal representative

Exclusion criteria

1. Behavioral disorders not compatible with interactive tool (major agitation, straight and self aggressiveness) 2. Uncontrolled seizure disorder despite treatment

Design outcomes

Primary

MeasureTime frameDescription
Correlation between number of successful attempts and intellectual disability evaluated by Intelligence quotient (IQ) or age of developmentup to 3 monthsTest performed 1 time during a visit (1 day) can be repeated (for a maximum of 15 patients) within 3 months if an adaptation of the interactive tool is necessary

Secondary

MeasureTime frame
Number of errors during the testup to 3 months
Time to reach each level of the testup to 3 months
Time to reach maximum level of the testup to 3 months
Maximal reached level for each testup to 3 months
Fixing time for eye trackingup to 3 months
Successful test numbers in each levelup to 3 months
Correlation with Intelligence quotient (IQ) or age of development according to intellectual disability severityup to 3 months
Total test durationup to 3 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026